Page 7 - Glenmark Pharmaceuticals

Nifty view and stock calls by Anand Rathi: Buy Glenmark Pharma, MPhasis

Glenmark Pharma's stock is taking the support of a rising trend line

Glenmark to launch higher strength of FabiFlu to manage Covid-19 dosage

The higher strength will improve compliance for patients by effectively reducing the number of tablets required per day

Stock calls by Nilesh Jain of Anand Rathi: Buy Glenmark Pharma, Tata Elxsi

Glenmark's stock has reclaimed its short term 21-DMA

Glenmark Pharma surges 6% as S&P Global sees stable cash flow in 2 years

Glenmark's operating cash flows, lower capital investments, and plans to channel proceeds from the sale of non-core assets to pay debt should improve its ratio of funds from operations to debt

Glenmark Pharmaceuticals declines 13% in two days on profit booking

The stock has jumped 40 per cent in the intra-day trade on Monday after the firm received approval for Favipiravir's (Fabiflu), a potential Covid-19 drug, by the Drug Controller General of India

Coronavirus updates: Delhi second most-affected state; drug for patients

Donald Trump may announce foreign workers' visa restrictions today, protect Americans struggling with a job market devastated by the coronavirus pandemic

Glenmark drug for mild Covid patients hits market, priced at Rs 103 a pill

FabiFlu is generic version of oral antiviral favipiravir; almost 80% patients are mildly sick, market potential for the oral drug is huge

Favipiravir shows improvement in moderate Covid-19 cases: Glenmark

The domestic pharma giant announced the launch of the first oral Favipiravir in the brand name "FabiFlu" claiming that it is backed by strong clinical evidence

Glenmark launches Covid-19 drug FabiFlu, priced at Rs 103 per tablet

FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19, it said in a statement

Glenmark Pharma gets USFDA nod for drug to treat multiple sclerosis

The capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis

Glenmark to begin clinical trial in India to test Covid-19 drug combination

Drugmakers across the world have been rushing to develop a treatment or vaccine for the fast-spreading coronavirus, which has infected 5.5 million people globally, killing more than 345,000

Govt mulls faster drug approval process, regulatory system overhaul

The industry, which has been lobbying for faster approvals for quite some time now, says the current pandemic should help expedite the reforms process

Strides Pharma to conduct trials for potential Covid-19 drug Favipiravir

Favipiravir is manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug in the country in 2014

Mumbai docs want key drugs made available fast as hospital wards swell up

If patients recover faster, they needn't stay in hospital for 14 days and this could free up beds; Remdesivir and Favipiravir are in the process of being made available in India

Covid-19: Pune-based drug firm to export favipiravir to 18 countries

Favipiravir is under trial in many countries as a potential treatment for Covid-19

Top 10 biz headlines: RIL results, FMCG mkt to see 'slowest' growth & more

Here are the top 10 business headlines this morning

In race to stop Covid-19, Indian drugmakers to conduct clinical trials

Glenmark, Zydus Cadila to start trials in May

Glenmark gets DCGI nod for clinical trials of potential Covid-19 drug

As per the clinical trial protocol approved, 150 subjects with mild to moderate Covid-19 will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care

Strong outlook, attractive valuations driving Glenmark's bounce back

US growth remains crucial for earnings upgrades, while licensing deals can help reduce both, costs and debt

Street positive in Hindustan Unilever's ability to scale up VWash

Strong distribution network and company's cost efficiency would help increase sales of the acquired high-margin portfolio